Stay updated on Safe Doses CX-2029 in Solid Tumors and DLBCL Clinical Trial
Sign up to get notified when there's something new on the Safe Doses CX-2029 in Solid Tumors and DLBCL Clinical Trial page.

Latest updates to the Safe Doses CX-2029 in Solid Tumors and DLBCL Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedRevision label updated from v3.2.0 to v3.3.2; no study content or functionality changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check28 days agoChange DetectedRemoved the government funding notice about NIH operating status; core study details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check49 days agoChange DetectedThe two screenshots show the same study page with only minor layout adjustments and an updated last-updated timestamp; there are no changes to eligibility criteria, primary or secondary outcomes, enrollment, or study status. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check71 days agoChange DetectedAdded a government-status notice, confirmed NIH Clinical Center is open, added new condition 'Malignant lymphoma, large B-cell, diffuse' and revision v3.2.0; removed 'Carcinoma of esophagus' and revision v3.1.0.SummaryDifference5%

- Check78 days agoChange DetectedVersion upgraded to v3.1.0 with removal of the term 'Diffuse large b-cell lymphoma'.SummaryDifference0.3%

- Check92 days agoChange DetectedUpdated to Revision v3.0.2; removed Back to Top link.SummaryDifference0.3%

Stay in the know with updates to Safe Doses CX-2029 in Solid Tumors and DLBCL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safe Doses CX-2029 in Solid Tumors and DLBCL Clinical Trial page.